Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for enhancing 13-valent pneumococcal polysaccharide protein bonder immunogenicity

A pneumococcal polysaccharide, immunogenic technology, applied in the direction of carrier-binding antigen/hapten components, antibacterial drugs, pharmaceutical formulations, etc., can solve the problems of immunogenic differences, protective limitations, and large immunogenicity variability

Active Publication Date: 2014-10-15
KANVAX BIOPHARM
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the immunogenicity of the existing pneumococcal polysaccharide-protein conjugate vaccines on the market is highly variable. This variability is not only due to the structural differences of polysaccharides of different serotypes, but also the use of different immunogenic protein carriers. It is also the main cause of the immunogenic difference of 13-valent pneumococcal polysaccharide protein conjugates
In certain high-risk populations, such as children, the elderly, or those who are immunocompromised, low-immunogenicity polysaccharide-protein conjugate vaccines are less effective and have limited protection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for enhancing 13-valent pneumococcal polysaccharide protein bonder immunogenicity
  • Method for enhancing 13-valent pneumococcal polysaccharide protein bonder immunogenicity
  • Method for enhancing 13-valent pneumococcal polysaccharide protein bonder immunogenicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The following examples illustrate specific implementation methods of the present invention, but are not limited to the following examples.

[0032] First step, preparation of carrier protein and pneumococcal polysaccharide

[0033] In order to demonstrate the effectiveness of the present invention, two carrier proteins were prepared, namely the protein carrier P2CRM197A containing P2 and the protein carrier CRM197A not containing P2. Among them, the CRM197A protein carrier is used to synthesize the 13-valent pneumococcal polysaccharide-CRM197A conjugate sample for control.

[0034] 1. Design of amino acid sequences of CRM197A protein carrier and P2CRM197A protein carrier

[0035] 1. Design of amino acid sequence of CRM197A protein carrier

[0036] Diphtheria toxin is expressed in Bacillus diphtheriae by β phage with diphtheria toxin gene, and exists in the form of polypeptide in bacterial cytoplasm, which is composed of 560 amino acids and has a molecular weight of 62...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for enhancing 13-valent pneumococcal polysaccharide protein bonder immunogenicity, and the method is as follows: adding all-powerful epitope peptide (P2) into CRM197A (A chain of diphtheria toxin variant 197), using genetic recombinant Escherichia coli to produce a P2-containing protein carrier P2CRM197A of the A chain of the diphtheria toxin variant 197 (CRM197); and connecting 13 different serotype polysaccharides with the P2-containing protein carrier P2CRM197A by covalent bonds to form a 13-valent pneumococcal polysaccharide-P2CRM197A bonder; compared with a 13-valent pneumococcal polysaccharide-CRM197A bonder obtained by a corresponding protein carrier CRM197A which does not contain the all-powerful epitope peptide (P2), the immunogenicity of the 13-valent pneumococcal polysaccharide-P2CRM197A bonder obtained by the method is increased by 3-5 times than that of a contrast.

Description

technical field [0001] The present invention relates to a method for enhancing the immunogenicity of 13-valent pneumococcal polysaccharide protein conjugates. Background technique [0002] When the polysaccharide is covalently linked to the protein carrier, the polysaccharide of the hapten can be converted into the whole antigen, so that the immunogenicity of the polysaccharide is enhanced. The polysaccharide-protein conjugate vaccine synthesized in this way has been widely used in children, and successfully prevented the infection of bacteria including pneumococcus, meningococcus and Haemophilus epidemic b. [0003] There are various protein carriers for the synthesis of polysaccharide-protein conjugates, such as tetanus toxoid, diphtheria toxoid, diphtheria toxin variant CRM197, and Haemophilus epidemic surface protein D produced by genetic recombination technology; The immunogenicity of polysaccharide-protein conjugates synthesized by different protein carriers is differ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/385A61K47/48A61P31/04
Inventor 李建平
Owner KANVAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com